Banque Cantonale Vaudoise Invests $2.31 Million in Humana Inc. (NYSE:HUM)

Key Points

• Banque Cantonale Vaudoise has acquired 8,721 shares of Humana Inc. (NYSE:HUM) in the first quarter, amounting to a value of approximately $2.3 million.
• Analysts have mixed ratings for Humana, with a consensus rating of "Hold" and a target price averaging around $282.43, while Oppenheimer has set a more optimistic target of $310.00.
• Humana's recent quarterly earnings showed a significant increase, with earnings per share of $11.58, surpassing estimates and reflecting an 8.4% year-over-year revenue growth.

Banque Cantonale Vaudoise purchased a new stake in shares of Humana Inc. (NYSE:HUM - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 8,721 shares of the insurance provider's stock, valued at approximately $2,308,000.

Other large investors have also recently bought and sold shares of the company. Dodge & Cox lifted its holdings in Humana by 106.7% during the 4th quarter. Dodge & Cox now owns 10,198,040 shares of the insurance provider's stock worth $2,587,345,000 after purchasing an additional 5,264,045 shares during the last quarter. Pzena Investment Management LLC increased its stake in Humana by 6.1% during the 1st quarter. Pzena Investment Management LLC now owns 3,828,923 shares of the insurance provider's stock worth $1,013,133,000 after acquiring an additional 219,541 shares during the period. Geode Capital Management LLC increased its stake in Humana by 2.3% during the 4th quarter. Geode Capital Management LLC now owns 2,883,614 shares of the insurance provider's stock worth $729,658,000 after acquiring an additional 63,562 shares during the period. Invesco Ltd. increased its stake in Humana by 29.8% during the 4th quarter. Invesco Ltd. now owns 2,397,808 shares of the insurance provider's stock worth $608,348,000 after acquiring an additional 550,692 shares during the period. Finally, T. Rowe Price Investment Management Inc. increased its stake in Humana by 11.1% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,605,771 shares of the insurance provider's stock worth $407,401,000 after acquiring an additional 160,952 shares during the period. 92.38% of the stock is owned by institutional investors and hedge funds.

Humana Price Performance

Shares of HUM traded down $2.68 during midday trading on Friday, hitting $247.19. 1,756,006 shares of the company traded hands, compared to its average volume of 1,854,830. The firm has a 50 day moving average of $234.64 and a 200-day moving average of $255.48. Humana Inc. has a 52 week low of $206.87 and a 52 week high of $382.72. The stock has a market cap of $29.73 billion, a price-to-earnings ratio of 18.97, a PEG ratio of 1.66 and a beta of 0.44. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.91 and a current ratio of 1.95.

Humana (NYSE:HUM - Get Free Report) last issued its quarterly earnings data on Wednesday, July 30th. The insurance provider reported $6.27 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.32 by ($0.05). Humana had a net margin of 1.28% and a return on equity of 13.67%. The business had revenue of $32.39 billion for the quarter, compared to analysts' expectations of $31.85 billion. During the same period in the previous year, the business earned $6.96 earnings per share. The business's quarterly revenue was up 9.6% compared to the same quarter last year. On average, analysts forecast that Humana Inc. will post 16.47 EPS for the current fiscal year.

Analysts Set New Price Targets

HUM has been the topic of a number of recent research reports. Truist Financial lowered their price objective on Humana from $280.00 to $260.00 and set a "hold" rating on the stock in a research note on Wednesday, July 16th. Robert W. Baird decreased their price target on Humana from $300.00 to $297.00 and set a "neutral" rating on the stock in a research note on Friday, July 25th. Cantor Fitzgerald reiterated a "neutral" rating and issued a $290.00 price target on shares of Humana in a research note on Thursday, May 1st. Wall Street Zen upgraded Humana from a "hold" rating to a "buy" rating in a research note on Sunday, July 20th. Finally, Guggenheim assumed coverage on Humana in a research note on Wednesday, April 9th. They issued a "buy" rating and a $326.00 price target on the stock. Sixteen equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, Humana has an average rating of "Hold" and a consensus price target of $281.62.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.